Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

Testosterone enanthate expiration?
Stribild expiry date?
What are the most memorable drug brands in oral factor b inhibitors? in united states
When is the expected fda decision date for apotex's ruxolitinib resubmission?
Drugpatentwatch evista historical sales market context?

Secukinumab inflammatory bowel disease?

See the DrugPatentWatch profile for Secukinumab

What inflammatory bowel diseases does secukinumab treat?

Secukinumab is an anti–IL-17A monoclonal antibody studied for inflammatory bowel disease (IBD). In practice, secukinumab’s IBD role is limited compared with other biologics that target TNF, integrins, or IL-12/23, and it is best thought of as an investigational or non-first-line option depending on the country and the specific IBD subtype (Crohn’s disease vs ulcerative colitis).

Where does secukinumab fit for Crohn’s disease vs ulcerative colitis?

Secukinumab targets IL-17A, but IL-17 biology differs across IBD subtypes. That biology mismatch is one reason secukinumab has not become a standard IBD biologic the way anti-TNF therapies have. For Crohn’s disease and ulcerative colitis, patients typically need therapies with evidence and regulatory approval for their specific condition and disease severity.

Why is IL-17 targeting a controversial strategy in IBD?

Clinical development of IL-17A inhibition in IBD has faced challenges because IL-17 pathways can play different roles in mucosal inflammation. As a result, IL-17 blockade has not produced consistently durable or broadly accepted benefits across Crohn’s disease and ulcerative colitis compared with established classes.

What are common alternatives patients search for?

Patients considering secukinumab often compare it with therapies that more commonly hold IBD indications, such as:
- Anti-TNF agents (for both Crohn’s disease and ulcerative colitis in many regions)
- Vedolizumab (anti-integrin)
- Ustekinumab (IL-12/23 pathway)
Because secukinumab is less established for IBD, switching discussions usually focus first on the therapies with clearer approval and outcomes for the patient’s exact IBD type and prior treatment history.

How do clinicians decide between biologics in IBD?

Treatment selection usually turns on:
- IBD type (Crohn’s vs ulcerative colitis)
- Prior therapy exposure (and whether disease is refractory)
- Severity and location of disease (especially for Crohn’s)
- Safety considerations and patient risk factors
- Country-specific prescribing guidance and approvals

Where can I find patent/exclusivity information for secukinumab?

If you’re researching commercial availability, patent status, or exclusivity for secukinumab, DrugPatentWatch.com tracks drug patents and related filings and can be a useful reference point: https://www.drugpatentwatch.com/

Sources

  1. https://www.drugpatentwatch.com/


Other Questions About Secukinumab :

Secukinumab infection risk? Secukinumab adverse effects? Secukinumab interactions? Secukinumab covid vaccine? Samsung Bioepsis has Secukinumab? Mmr vaccine and secukinumab? Who owns secukinumab?

AI-Drug Label Prescribing Information Alignment Report

Patient Risk: Low

Summary

The provided FDA label excerpts do not include any on-label statements regarding inflammatory bowel disease treatment by COSENTYX or comparative/“investigational/non-first-line” positioning. Several claims address IBD efficacy/role and comparative acceptance, which are unsupported by the supplied label information.

Category Scores

Indication
0
Poor
Warnings
20
Poor

Accurate Statements

Secukinumab is an anti–IL-17A monoclonal antibody.
Supported by provided label excerpts: 11 DESCRIPTION/12.1 Mechanism of Action describe secukinumab as an interleukin-17A antagonist and selectively binds IL-17A.
Secukinumab targets IL-17A.
Supported by provided label excerpts: 11 DESCRIPTION and 12.1 Mechanism of Action.

Unsupported Statements

Secukinumab has been studied for inflammatory bowel disease (IBD).
No FDA label excerpts provided in the prompt state that COSENTYX/secukinumab was studied for IBD (e.g., in Clinical Studies/IBD efficacy). The excerpts only mention IBD exacerbations as a warning, not study/efficacy evidence.
In practice, secukinumab’s role in IBD is limited compared with other biologics that target TNF, integrins, or IL-12/23.
No on-label comparative positioning or comparative effectiveness/role statements vs anti-TNF/integrin/IL-12/23 therapies were provided in the supplied label excerpts.
Secukinumab is considered an investigational or non-first-line option for IBD depending on the country and the specific IBD subtype (Crohn’s disease vs ulcerative colitis).
No label excerpt provided supports claims about being “investigational,” “non-first-line,” or country/subtype-dependent positioning.
IL-17 biology differs across IBD subtypes.
No mechanistic/label text about IL-17 biology differing across IBD subtypes was provided in the supplied excerpts.
A biology mismatch is one reason secukinumab has not become a standard IBD biologic the way anti-TNF therapies have.
No label excerpt provides reasons for non-adoption/comparative standard-of-care, or discusses “biology mismatch” as a cause.
IL-17 blockade has not produced consistently durable or broadly accepted benefits across Crohn’s disease and ulcerative colitis compared with established classes.
No label excerpt provided includes comparative statements about durability or acceptance across Crohn’s vs ulcerative colitis or against established classes.
Clinical development of IL-17A inhibition in IBD has faced challenges.
No label excerpt provided describes clinical development challenges for IL-17A inhibition in IBD.
IL-17 pathways can play different roles in mucosal inflammation.
No label excerpt provided supports this generalization about IL-17 pathway roles in mucosal inflammation.
Anti-TNF agents are used for both Crohn’s disease and ulcerative colitis in many regions.
No label excerpt provided supports comparative or regional use statements about anti-TNF agents for IBD.
Vedolizumab is an anti-integrin therapy.
Not supported or referenced in the COSENTYX label excerpts provided (and the label excerpts are about COSENTYX, not other drugs).
Ustekinumab is a therapy that targets the IL-12/23 pathway.
Not supported or referenced in the COSENTYX label excerpts provided (and the label excerpts are about COSENTYX, not other drugs).

Contradictions

Low

AI Statement
Secukinumab has been studied for inflammatory bowel disease (IBD).

Label Reference
Provided label excerpt section 5.4 only states: “Inflammatory Bowel Disease (IBD) exacerbations occurred in COSENTYX treated subjects.” There is no provided label excerpt stating efficacy/study outcomes for IBD.

Important Omissions

If discussing IBD in relation to COSENTYX, the supplied label excerpts specifically mention IBD exacerbations (Warnings and Precautions 5.4). The AI response does not mention this risk.
Importance: Moderate

Safety Assessment

Potential Patient Risk: Low
The unsupported claims primarily concern comparative effectiveness/positioning in IBD and general mechanistic statements. However, an omission exists: the label excerpt provided highlights IBD exacerbations, which the response does not mention.

Regulatory Assessment

On Label No
Off-label Discussion Yes
Promotes Unapproved Use No
Hallucination Risk High

Recommendation

Mostly Aligned

Primary Issue
Several claims about IBD study status, comparative effectiveness, and being “investigational/non-first-line” are not supported by the provided COSENTYX label excerpts.

Suggested Improvement
Limit statements to what the supplied label excerpts support (e.g., IL-17A antagonism) and, if mentioning IBD, include the label-provided safety warning that IBD exacerbations occurred. Remove or qualify comparative/positioning assertions unless supported by the provided label text.

Drug Brand Mention Assessment

Branding Score
22
Visibility
18
Mentioned
Ranking
#1
Sentiment
25
Recommendation Status
conditional
Brand Perception
Best Known For

anti–IL-17A monoclonal antibody studied for inflammatory bowel disease (IBD)

Core Claims
  • Secukinumab is an anti–IL-17A monoclonal antibody studied for inflammatory bowel disease (IBD).
  • In practice, secukinumab’s IBD role is limited compared with other biologics that target TNF, integrins, or IL-12/23.
  • Secukinumab is best thought of as an investigational or non-first-line option depending on the country and the specific IBD subtype (Crohn’s disease vs ulcerative colitis).
  • IL-17 blockade has not produced consistently durable or broadly accepted benefits across Crohn’s disease and ulcerative colitis compared with established classes.
Differentiators
  • It targets IL-17A, but IL-17 biology differs across IBD subtypes.
  • Its IBD role is limited compared with biologics targeting TNF, integrins, or IL-12/23.
  • It is described as investigational or non-first-line depending on country and subtype.
Pricing Perception: Not Mentioned
Competitors Mentioned
Company Visibility Sentiment Rank Recommended
Vedolizumab 0%
0 # No
Ustekinumab 0%
0 # No